Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
前收盘价
US$1.45
−US$0.05 · -3.33%
盘中时间采用ET。市场数据可能有所延迟。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日内区间
当前US$1.45
52周区间
当前US$1.45
盘中时间采用ET。市场数据可能有所延迟。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日内区间
当前US$1.45
52周区间
当前US$1.45
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 2831.2万 USD |
| 销货成本 | 112.8万 USD | 117.8万 USD | 117万 USD | 105.7万 USD | 123.4万 USD |
| 毛利 | −112.8万 USD | −117.8万 USD | −117万 USD | −105.7万 USD | 2707.8万 USD |
| 研究与开发 | 2490.3万 USD | 3365.6万 USD | 2267.9万 USD | 1704.6万 USD | 4860.7万 USD |
| 销售、一般及管理费用 | 1281.1万 USD | 1133万 USD | 1189.6万 USD | 563万 USD | 1777.8万 USD |
| 营业费用 | 3658.6万 USD | 4380.8万 USD | 3457.5万 USD | 2267.6万 USD | 6638.5万 USD |
| 利息收入 | 77.6万 USD | 77.7万 USD | 37.3万 USD | 6.48万 USD | 3392 USD |
| 利息支出 | 113.3万 USD | 45.5万 USD | 105.9万 USD | 359.58万 USD | 87.64万 USD |
| 折旧和摊销 | 112.8万 USD | 117.8万 USD | 117万 USD | 105.7万 USD | 25.15万 USD |
| 营业利润 | −3771.4万 USD | −4498.6万 USD | −3574.5万 USD | −2373.3万 USD | −3930.7万 USD |
| 净利润 | −3957.1万 USD | −5189.8万 USD | −3519.5万 USD | −2820.8万 USD | −2640.07万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$17.00
上涨空间 1072.41%评级样本有限,仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年6月2日 | 1:10 | — | — |
已生效 2023年6月2日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI54.99万0.00%6893亿 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM47.57万0.00%715.37亿 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF24.12万0.00%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO18.51万0.00%127.32亿 USD0.24%US$320.43-3.57%
Vanguard Russell 2000 ETFVTWO15.84万0.00%168亿 USD0.06%US$103.76-2.76%
iShares Micro-Cap ETFIWC6.92万0.01%10.88亿 USD0.60%US$157.87-3.19%
Vanguard Russell 2000 Growth ETFVTWG3.16万0.00%14亿 USD0.06%US$234.06-3.57%
Global X - Russell 2000 ETFRSSL1.15万—14.05亿 USD0.08%US$100.61-2.74%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Russell 2000 Growth ETFVTWG
Global X - Russell 2000 ETFRSSLAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。